Medtronic PLC $MDT Shares Sold by Aberdeen Group plc

Aberdeen Group plc cut its stake in Medtronic PLC (NYSE:MDT) by 2.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,547,543 shares of the medical technology company’s stock after selling 55,114 shares during the quarter. Aberdeen Group plc owned approximately 0.20% of Medtronic worth $240,437,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. GF Fund Management CO. LTD. raised its position in Medtronic by 0.4% during the third quarter. GF Fund Management CO. LTD. now owns 35,405 shares of the medical technology company’s stock worth $3,372,000 after acquiring an additional 143 shares during the period. TCTC Holdings LLC increased its stake in shares of Medtronic by 13.8% during the third quarter. TCTC Holdings LLC now owns 40,083 shares of the medical technology company’s stock worth $3,818,000 after purchasing an additional 4,876 shares in the last quarter. Cidel Asset Management Inc. raised its position in shares of Medtronic by 2.7% during the 3rd quarter. Cidel Asset Management Inc. now owns 9,851 shares of the medical technology company’s stock worth $938,000 after purchasing an additional 255 shares during the last quarter. BTC Capital Management Inc. lifted its stake in Medtronic by 0.9% in the 3rd quarter. BTC Capital Management Inc. now owns 51,190 shares of the medical technology company’s stock valued at $4,874,000 after buying an additional 473 shares in the last quarter. Finally, WJ Financial Advisors LLC purchased a new position in Medtronic in the 3rd quarter valued at about $259,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Price Performance

Medtronic stock opened at $99.57 on Friday. The company’s 50 day simple moving average is $99.28 and its 200-day simple moving average is $96.43. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a market capitalization of $127.65 billion, a price-to-earnings ratio of 26.84, a price-to-earnings-growth ratio of 2.62 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the prior year, the company earned $1.26 EPS. Medtronic’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Wall Street Analyst Weigh In

MDT has been the topic of several research reports. Morgan Stanley raised their target price on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Wells Fargo & Company began coverage on shares of Medtronic in a report on Friday, January 30th. They set an “overweight” rating and a $114.00 target price for the company. Daiwa Securities Group increased their target price on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Finally, TD Cowen restated a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Sixteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $111.21.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA cleared Medtronic’s Stealth AXiS system — an integrated planning, navigation and robotics platform for spine surgery that expands the company’s procedural addressable market and supports hardware/software recurring revenue potential. This is a material product‑launch catalyst for spine and future cranial/ENT applications. PR Newswire
• Positive Sentiment: Independent coverage and price‑target lifts: Barclays initiated coverage with an Overweight and $116 PT, and Needham upgraded to Buy with a $121 PT — both signal analyst conviction that recent product momentum and margins support upside from current levels. Benzinga Needham Upgrade
• Positive Sentiment: Market commentary highlights improving returns/operational momentum that could support multiple expansion if sustained — a constructive narrative for longer‑term investors. Yahoo Finance
• Neutral Sentiment: Q3 FY2026 earnings preview: analysts outline what to watch in the upcoming report (revenue cadence, procedure volumes, and guidance) — an event that could be a short‑term catalyst but not new information. MSN Earnings Preview
• Neutral Sentiment: Dividend/income writeups underscore MDT’s ~2.8% yield and ways to generate cash flow; supportive for income investors but a limited driver of near‑term price moves. Benzinga Dividend
• Negative Sentiment: Geopolitical and China exposure risks: analysis highlights tariffs and China’s volume‑based procurement (VBP) program as potential headwinds to margins and growth in a key market — a meaningful downside risk that can compress near‑term revenue and investor sentiment. Seeking Alpha

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).